Long-Acting/Extended Release (LA/ER) Antiretroviral Research Resource Program (LEAP) Investigator Meeting & Annual Workshop - 2021

Date: 
3/5/21

Friday March 5, 2021
ZOOM VIRTUAL WEBCAST

 

Carl Dieffenbach, Directo, Division of AIDS, NIH
Welcome
[video-only]

Charles Flexner, Johns Hopkins University
Where are we LEAPing Next?!
[video/slides]

PLENARY 1: Current Status of Existing Programs:

William Spreen, ViiV Healthcare
Current status of LA/ER Cabotegravir and Rilpivirine including pipeline report on novel CBT formulations
[video/slides

Jay Grobler, Merck
Current status of the Merck LA/ER pipeline
[video/slides]

Martin Rhee, Gilead Sciences
Current status of the Gilead LA/ER pipeline
[video/slides]

Marco Siccardi, University of Liverpool
Update from the LEAP Modeling and Simulation Core
[video/slides]

Susan Swindells, University of Nebraska Medical Center
LEAP TB:  Update from the LEAP Working Group on Development of Long-Acting Approaches to the Treatment of Tuberculosis
[video/slides]

Plenary Session II: Novel technologies and approaches:

Erika Englund, Food and Drug Administration
Chemistry, Manufacturing and Controls (CMC): Considerations for Extended-Release Injectable Formulations
[video/slides]

Nicole Ammerman, Johns Hopkins University
Injection volumes: possible role of recombinant hyaluronidase and other approaches
[video/slides]

Edmund Capparelli, University of California, San Diego
Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
[video/slides]

Andrew Owen, University of Liverpool
Update from LONGEVITY
[video/slides]

Rodney Ho, University of Washington
Update from the Targeted, Long-acting and Combination Anti-Retroviral Therapy (TLC-ART) program
[video/slides]
 
Lobna Gaayeb, Medicine Patent Pool
Medicines Patent Pool Long Acting Initiatives
[video/slides]

Focus Group Summary Reports:

Dave Thomas, Johns Hopkins University, Andrew Owen, Liverpool; Craig McClure as Rapporteur
Group 1: What should the agenda be in coming year for the LEAP Viral Hepatitis Working Group?
[video/slides]

Raphael Landovitz, UCLA, and Beatriz Grinsztejn, Fiocruz; Andy Kaytes as Rapporteur
Group 2: What HPTN 083 and 084 teaches us about Injectable LA ARV’s: What have we learned, and what do we need to learn next? What to do about the tail? How to avoid oral formulations at the end of LA PrEP strategies?
[video/slides]

Katie Bar, U Penn, and Marina Caskey, Rockefeller University; Roy (Trip) Gulick, Cornell University, as Rapporteur
Group 3: Designing and implementing clinical studies of monoclonal antibodies for HIV and SARS-CoV-2: What have we learned to date?
[video/slides]

Elaine Abrams, Columbia University and Mark Mirochnick, Boston University; Polly Clayden Rapporteur
Group 4: Infants, children, and pregnant women: How to make better progress in clinical studies of LA formulations?
[video/slides]